Thomas Pezawas1, André Diedrich2, David Robertson2, Robert Winker3, Bernhard Richter1, Li Wang4, Herwig Schmidinger1. 1. Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria. 2. Departments of Medicine, Clinical Pharmacology, Pharmacology, and Neurology, Vanderbilt Autonomic Dysfunction Center, Nashville, TN, USA. 3. Health and Prevention Center, Hera, Vienna, Austria. 4. Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN, USA.
Abstract
BACKGROUND: Risk of arrhythmic death is considered highest in ischemic heart disease with severe left ventricular ejection fraction (LVEF) reduction. Non-invasive testing should improve decision-making of prophylactic defibrillator (ICD) implantation. DESIGN: We enrolled 120 patients with ischemic heart disease and LVEF < 50% and 30 control subjects without ischemic heart disease and normal LVEF. An initial assessment, a second assessment after 3 years and a final follow-up comprised of pharmacological baroreflex testing (BRS), short-term spectral [low-frequency (LF) to high-frequency (HF) ratio] and long-term time-domain analysis of heart rate variability (SDNN), exercise Microvolt T-wave alternans (MTWA) and others. RESULTS: The median follow-up was 7·5 years. Resuscitated cardiac arrest and arrhythmic death due to ventricular arrhythmias ≥ 240/min was observed in 18% and 15% of patients, respectively. Cardiac death was observed in 28% of patients. The incidence of arrhythmic death and resuscitated cardiac arrest was identical in patients with ischemic heart disease with LVEF < 30% and ≥ 30%. No significant difference between subgroups with LVEF of < 30%, 30-39% and ≥ 40% was found either. MTWA, BRS, SDNN and LF to HF ratio failed to identify patients at risk of arrhythmic death in a multiple regression model. CONCLUSIONS: Ischemic heart disease patients with LVEF < 30% and ≥ 30% face the same risk of arrhythmic death. Stratification techniques fail to identify high-risk patients. Therefore, the current practice to constrain prophylactic ICDs to patients with severely reduced LVEF seems to be insufficient.
BACKGROUND: Risk of arrhythmic death is considered highest in ischemic heart disease with severe left ventricular ejection fraction (LVEF) reduction. Non-invasive testing should improve decision-making of prophylactic defibrillator (ICD) implantation. DESIGN: We enrolled 120 patients with ischemic heart disease and LVEF < 50% and 30 control subjects without ischemic heart disease and normal LVEF. An initial assessment, a second assessment after 3 years and a final follow-up comprised of pharmacological baroreflex testing (BRS), short-term spectral [low-frequency (LF) to high-frequency (HF) ratio] and long-term time-domain analysis of heart rate variability (SDNN), exercise Microvolt T-wave alternans (MTWA) and others. RESULTS: The median follow-up was 7·5 years. Resuscitated cardiac arrest and arrhythmic death due to ventricular arrhythmias ≥ 240/min was observed in 18% and 15% of patients, respectively. Cardiac death was observed in 28% of patients. The incidence of arrhythmic death and resuscitated cardiac arrest was identical in patients with ischemic heart disease with LVEF < 30% and ≥ 30%. No significant difference between subgroups with LVEF of < 30%, 30-39% and ≥ 40% was found either. MTWA, BRS, SDNN and LF to HF ratio failed to identify patients at risk of arrhythmic death in a multiple regression model. CONCLUSIONS:Ischemic heart diseasepatients with LVEF < 30% and ≥ 30% face the same risk of arrhythmic death. Stratification techniques fail to identify high-risk patients. Therefore, the current practice to constrain prophylactic ICDs to patients with severely reduced LVEF seems to be insufficient.
Authors: Thomas Pezawas; André Diedrich; Robert Winker; David Robertson; Bernhard Richter; Li Wang; Daniel W Byrne; Herwig Schmidinger Journal: Circ Arrhythm Electrophysiol Date: 2014-09-27
Authors: Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews Journal: N Engl J Med Date: 2002-03-19 Impact factor: 91.245
Authors: Andrea M Russo; Raymond F Stainback; Steven R Bailey; Andrew E Epstein; Paul A Heidenreich; Mariell Jessup; Suraj Kapa; Mark S Kremers; Bruce D Lindsay; Lynne Warner Stevenson Journal: J Am Coll Cardiol Date: 2013-03-01 Impact factor: 24.094
Authors: Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip Journal: N Engl J Med Date: 2005-01-20 Impact factor: 91.245
Authors: A J Moss; W J Hall; D S Cannom; J P Daubert; S L Higgins; H Klein; J H Levine; S Saksena; A L Waldo; D Wilber; M W Brown; M Heo Journal: N Engl J Med Date: 1996-12-26 Impact factor: 91.245
Authors: Heikki V Huikuri; Jari M Tapanainen; Kai Lindgren; Pekka Raatikainen; Timo H Mäkikallio; K E Juhani Airaksinen; Robert J Myerburg Journal: J Am Coll Cardiol Date: 2003-08-20 Impact factor: 24.094
Authors: Daniel M Bloomfield; Richard C Steinman; Pearila B Namerow; Michael Parides; Jorge Davidenko; Elizabeth S Kaufman; Timothy Shinn; Anne Curtis; John Fontaine; Douglas Holmes; Andrea Russo; Chuen Tang; J Thomas Bigger Journal: Circulation Date: 2004-09-27 Impact factor: 29.690
Authors: Heikki V Huikuri; M J Pekka Raatikainen; Rikke Moerch-Joergensen; Juha Hartikainen; Vesa Virtanen; Jean Boland; Olli Anttonen; Nis Hoest; Lucas V A Boersma; Eivind S Platou; Marc D Messier; Poul-Erik Bloch-Thomsen Journal: Eur Heart J Date: 2009-01-20 Impact factor: 29.983
Authors: Achim Leo Burger; Stefan Stojkovic; André Diedrich; Svitlana Demyanets; Johann Wojta; Thomas Pezawas Journal: Clin Biochem Date: 2020-06-04 Impact factor: 3.625
Authors: Stefan Stojkovic; Alexandra Kaider; Lorenz Koller; Mira Brekalo; Johann Wojta; Andre Diedrich; Svitlana Demyanets; Thomas Pezawas Journal: J Cell Mol Med Date: 2018-02-04 Impact factor: 5.295
Authors: Alfonso M Gañán-Calvo; Katerina Hnatkova; Álvaro Romero-Calvo; Juan Fajardo-López; Marek Malik Journal: Sci Rep Date: 2018-07-02 Impact factor: 4.379